United Kingdom

Takara Bio Inc (4974.T)

4974.T on Tokyo Stock Exchange

6:00am GMT
Change (% chg)

¥-84 (-3.98%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Wafergen Bio-Systems expects total revenue for Q4 2016 to be about $3.9 mln
Wednesday, 15 Feb 2017 

Wafergen Bio-systems Inc : Wafergen Bio-systems reports revenue growth in fourth quarter of 2016 . Sees FY 2016 revenue about $10.7 million . Wafergen Bio-Systems Inc - company expects total revenue for Q4 of 2016 to be approximately $3.9 million or a 62% increase .Wafergen Bio-Systems Inc - ended Q4 with cash of approximately $4.5 million, which includes initial $2.5 million advanced by Takara Bio USA Holdings, Inc.  Full Article

Takara Bio launches fully differentiated, Cellartis hiPS beta cells for research use
Wednesday, 24 Aug 2016 

Takara Bio Inc <4974.T> :Launch of fully differentiated, Cellartis hiPS beta cells for research use.  Full Article

Takara Bio completes share repurchase
Tuesday, 14 Jun 2016 

Takara Bio Inc <4974.T> :Says it completes repurchase of 477,600 shares of its common stock, for about 725 million yen in total, on June 14.  Full Article

Wafergen Bio-Systems and Takara Bio signs distribution agreement for Japan
Monday, 6 Jun 2016 

Wafergen Bio-systems Inc :Wafergen Bio-Systems and Takara Bio Inc Announce exclusive distribution agreement for japan.  Full Article

Wafergen to pay Takara Bio USA Holdings termination fee equal to $2 mln
Friday, 13 May 2016 

Wafergen Bio-Systems Inc :Upon termination of merger agreement co will be required to pay Takara Bio USA Holdings a cash termination fee equal to $2.0 million.  Full Article

Takara Bio unit to fully acquire WaferGen Bio-systems
Friday, 13 May 2016 

Takara Bio <4974.T>:Says its subsidiary Takara Bio USA Holdings Inc. signed a merger agreement to fully acquire WaferGen Bio-systems, Inc at up to $50 million.  Full Article

BRIEF-Takara Bio say first patient enrolled into phase I clinical trial of Oncolytic Virus HF10 in Japan

* Says the first patient with pancreatic cancer has been enrolled into Oncolytic Virus HF10(TBI-1401) phase I clinical trial in Japan on Sept. 26